Latest Ratios: P/E Ratio -4.2x · EV/EBITDA N/A · ROE -565.3%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $645M | $255M | $446M | $341M | $884M | $1.7B | — | — |
| Enterprise Value | $1.1B | $517M | $122M | $259M | $199M | $614M | $1.5B | — | — |
| P/E Ratio → | -4.22 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 1.65 | 1.98 | 1.88 | 3.11 | 8.71 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -565.3% | -565.3% | -81.5% | -58.2% | -39.3% | -29.8% | -59.3% | -230.2% | — |
| ROA | -135.8% | -135.8% | -63.4% | -50.1% | -36.7% | -28.4% | -51.6% | -66.7% | -50.1% |
| ROIC | — | — | -442.5% | -261.3% | -302.3% | -594.0% | -714.4% | -342.3% | — |
| ROCE | -251.8% | -251.8% | -81.7% | -62.5% | -47.2% | -34.5% | -50.5% | -128.1% | -50.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.21 | 0.15 | 0.01 | 0.01 | — | 2.48 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.86 | -0.83 | -0.78 | -0.95 | -0.97 | -0.46 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -63.28 | -63.28 | -33.28 | -52.40 | — | — | — | — | — |
Net cash position: cash ($150M) exceeds total debt ($21M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.77 | 0.77 | 5.92 | 13.33 | 12.29 | 19.55 | 29.36 | 1.35 | 14.24 |
| Quick Ratio | 0.77 | 0.77 | 5.92 | 13.33 | 12.29 | 19.55 | 29.36 | 1.35 | 13.72 |
| Cash Ratio | 0.60 | 0.60 | 4.85 | 11.23 | 9.18 | 18.09 | 27.60 | 1.05 | 12.41 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $94M | $67M | $51M | $42M | $40M | $36M | $22M | $6M |
Clinical trial funding runway
As reported in financial statements, COMPASS Pathways' ROIC has remained consistently negative, bottoming out at -179.6% in 2024Q4, which underscores the company's inability to generate returns on invested capital while it continues to prioritize heavy R&D spending over immediate operational profitability or capital efficiency.
The persistent negative ROIC trend reflects the structural reality of a pre-revenue biotech firm where capital is consumed by clinical trials rather than deployed into productive, return-generating assets. Investors should monitor whether this trend begins to moderate as the company approaches potential commercialization, though current figures suggest that capital is being eroded rather than compounded.
Based on recent SEC filings, the company's current ratio has experienced a dramatic contraction from 15.23 in 2024Q1 to 0.77 in 2025Q4, indicating that the firm's short-term liquidity position has become increasingly strained as cash reserves are aggressively deployed to fund ongoing Phase III clinical trial infrastructure.
A current ratio falling below 1.0 suggests that the company's ability to cover short-term obligations without external financing or asset liquidation is becoming compromised. This rapid depletion of liquidity warrants further investigation into the company's remaining cash runway and the potential necessity for dilutive capital raises to sustain operations through the next data readout.
According to reported figures, the company maintains a conservative debt profile with a D/E ratio of 0.01 as of 2026Q1, yet this low leverage appears to be a function of limited access to traditional credit markets rather than a strategic choice to avoid interest-bearing obligations during development.
While the low debt-to-equity ratio might appear favorable in isolation, it provides little insight into the company's actual financial health given the absence of revenue to service even minor debt obligations. The reliance on equity financing over debt suggests that the firm's risk profile is primarily managed through shareholder dilution rather than traditional balance sheet leverage.
As indicated by the provided financial data, the market's reliance on traditional P/E or EV/EBITDA multiples is fundamentally flawed for a pre-revenue entity like COMPASS Pathways, as these metrics obscure the company's true operational status and the binary nature of its clinical trial outcomes.
Investors should instead focus on enterprise value relative to clinical milestones or cash burn rates, as traditional valuation ratios are inapplicable in the absence of earnings. Applying standard valuation frameworks to this business model risks misinterpreting the company's speculative value as a reflection of current operational performance rather than future potential.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CMPS stock.
COMPASS Pathways plc's current P/E ratio is -4.2x. This places it at the 50th percentile of its historical range.
COMPASS Pathways plc's return on equity (ROE) is -565.3%. The historical average is -83.1%.
Based on historical data, COMPASS Pathways plc is trading at a P/E of -4.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.